Trials / Unknown
UnknownNCT02980315
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The Second Hospital of Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.
Detailed description
Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | CAR-T cells | the patients treat with CAR-T cells |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-12-02
- Last updated
- 2016-12-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02980315. Inclusion in this directory is not an endorsement.